About: C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.82 (-2.08%)
CCCC NASDAQ C4 Therapeutics Inc
C4 Therapeutics Inc share price
CCCC price activity
Último preço
$ 2,820
Variação (24h)
-0,06 USD (-2,08%)
Volume
2.27M
Volume (média 4 sem.)
-
Abertura
$ 2,85
Variação do dia
$ 2,82 - $ 2,95
Fechamento anterior
$ 2,88
Último negócio
07 Oct, 8:00 pm GMT+0
Atrasado
07 Oct, 8:00 pm GMT+0
CCCC price performance
Atrasado
07 Oct, 8:00 pm GMT+0
quote.marketSignals